Tracking the fate of adoptively transferred myeloid-derived suppressor cells in the primary breast tumor microenvironment
Tracking the fate of adoptively transferred myeloid-derived suppressor cells in the primary breast tumor microenvironment
Jaclyn Sceneay 1 2
Christoph M. Griessinger 0 1 2
Sabrina H. L. Hoffmann 0 2
Shu Wen Wen 1 2
Christina S. F. Wong 1 2
Sophie Krumeich 1 2
Manfred Kneilling 0 2
Bernd J. Pichler 0 2
Andreas MoÈ ller 1 2
☯ These authors contributed equally to this work. 2
0 Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University TuÈ bingen, T uÈbingen, Germany, 3 Department of Dermatology, Eberhard Karls University TuÈbingen, TuÈ bingen, Germany, 4 School of Medicine, University of Queensland , Brisbane , Australia
1 Tumor Microenvironment Laboratory, QIMR Berghofer Medical Research Institute , Herston , Australia
2 Editor: Fabrizio Mattei, Istituto Superiore di Sanità , ITALY
Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature myeloid progenitor cells that are expanded in cancer and act as potent suppressors of the anti-tumor immune response. MDSCs consist of two major subsets, namely monocytic (M-) MDSCs and granulocytic (G-) MDSCs that differ with respect to their phenotype, morphology and mechanisms of suppression. Here, we cultured bone marrow cells with IL-6 and GM-CSF in vitro to generate a population of bone marrow MDSCs (BM-MDSCs) similar to G-MDSCs from tumor-bearing mice in regards to phenotype, morphology and suppressivefunction. Through fluorescent labeling of these BM-MDSCs and optical imaging, we could visualize the recruitment and localization of BM-MDSCs in breast tumor-bearing mice in vivo. Furthermore, we were able to demonstrate that BM-MDSCs home to primary and metastatic breast tumors, but have no significant effect on tumor growth or progression. Ex vivo flow cytometry characterization of BM-MDSCs after adoptive transfer demonstrated both organ-and tumor-specific effects on their phenotype and differentiation, demonstrating the importance of the local microenvironment on MDSC fate and function. In this study, we have developed a method to generate, visualize and detect BM-MDSCs in vivo and ex vivo through optical imaging and flow cytometry, in order to understand the organ-specific changes rendered to MDSCs in breast cancer.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information
Funding: This work was supported by the
Research Fellowship of the German Research
Foundation (GR4017/1-1) and a FortuÈne-Junior
Grant (2309-0-0) of the Medical Faculty for CMG;
the University of TuÈbingen and the Swiss Werner
Siemens Foundation for BJP; the National Health
and Medical Research Council Australia (NHMRC,
Expansion of suppressive cell populations represents a key strategy employed by tumors to
escape immune surveillance. Myeloid-derived suppressor cells (MDSCs) are one such
population, consisting of myeloid progenitor cells and immature myeloid cells [
heterogeneous population can differentiate into mature granulocytes, macrophages and dendritic cells
APP1068510), Cancer Council Queensland
(6156), and National Breast Cancer Foundation
(Australia) fellowship and grant to AM (ECF-11-09,
NC-13-26). The funders had no role in study
design, data collection and analysis, decision to
publish, or preparation of the manuscript.
Competing interests: The authors have declared
that no competing interests exist.
Abbreviations: Arg1, Arginase 1; BL,
Bioluminescence; BMDCs, Bone marrow-derived
cells; BM-MDSCs, Bone Marrow myeloid-derived
suppressor cells; DCs, Dendritic cells; FL,
Fluorescence; FACS, Fluorescence activated cell
sorting; i.c., Intra cardiac; iNos, Inducible nitric
oxide synthase; IL-6, Interleukin 6; i.p., Intra
peritoneal; i.v., Intra venous; GM-CSF,
Granulocytemacrophage colony-stimulating factor; G-MDSCs,
Granulocytic myeloid-derived suppressor cells;
Luc, Luciferase; MRI, Magnetic Resonance
Imaging; MFP, Mammary fat pad; MDSCs,
Myeloid-derived suppressor cells; M-MDSCs,
Monocytic myeloid-derived suppressor cells; NK
cells, Natural killer cells; OI, Optical imaging; PET,
Positron Emission Tomography; PyMT-MMTV,
Polyoma middle-T mouse mammary tumor virus;
Tregs, Regulatory T helper cells; TME, Tumor
(DCs) in healthy individuals, but in cancer patients, inhibition of differentiation results in the
accumulation of an immature population consisting of myeloid precursors [
importance of immunosuppressive MDSCs in cancer is well established, with the number of
circulating MDSCs correlating with metastatic burden and cancer stage . However, their biology is
not well understood. MDSCs were initially defined based on the co-expression of CD11b and
Gr-1 in tumor-bearing mice [
]. More recently, two distinct Ly6 superfamily receptors,
Ly6C and Ly6G, have been used to further define different MDSC subpopulations into
CD11b+/Ly6Cmed/int/+/Ly6G+ polymorphonuclear or granulocytic MDSCs (G-MDSCs), and
CD11b+/Ly6Chigh/+/Ly6G- monocytic MDSCs (M-MDSCs) [
]. In humans, these
granulocytic and monocytic populations are defined as CD11b+/CD14-/CD15+ and CD11b+/CD14+,
The immunosuppressive mechanisms of these subsets are also distinct. G-MDSCs suppress
CD8+ T cells primarily through ROS production and arginase (Arg)-1, while M-MDSCs
suppress CD8+ T cells via inducible nitric oxide synthase (iNOS) and reactive nitrogen species
[3,10±12]. While G-MDSCs are the predominant population in tumor-bearing mice [
prevalence and ratio of the different MDSC subsets is highly variable depending on the tumor
type and tissue in question [
], and much remains unknown regarding the factors that
regulate their function and mobilization in different tumor models. G-MDSCs are generally the
prevailing population in lymphoid organs, but this ratio can be skewed to favour M-MDSCs in
the tumor, indicating that MDSC differentiation, migration and function is strongly
influenced by factors in the local environment [
]. Cytokines, chemokines and pro-inflammatory
factors produced by both tumor and stromal cells promote myelopoiesis, block maturation of
myeloid cells and recruit MDSCs to the tumor microenvironment (TME) [2,9,15±24].
Suppressive cell populations such as MDSCs represent major impediments to the
development of effective cancer treatments, as their ability to suppress anti-cancer immunity
compromises the effectiveness of immune-based therapies [
]. Research efforts have focused on
eliminating or inactivating MDSCs in order to restore anti-tumor immunity and reverse the
suppressive state of the TME [
]. In order to successfully target MDSCs however, it is
necessary to more closely understand the mechanisms governing their mobilization, trafficking,
function and differentiation potential. As MDSCs do not exist in the same state in naïve mice
, current methods of study involve enrichment and isolation through flow cytometry from
the different tissues of tumor-bearing mice or patient samples, which can result in very low
yields. MDSCs isolated from tumor-bearing mice do not survive long or proliferate in culture
], and very few studies have investigated the potential to generate MDSCs de novo. Recently,
a protocol to generate immunosuppressive MDSCs from bone marrow-derived cells (BMDCs)
cultured with granulocyte macrophage colony stimulating factor (GM-CSF) and interleukin 6
(IL-6) was established [
]. GM-CSF has been identified as the main cytokine responsible for
MDSC expansion in vivo in numerous studies [11,21,28,30±32], while the pro-inflammatory
cytokine IL-6 reportedly contributes to MDSC accumulation and suppressive function
]. Here, we utilize MDSCs generated from BMDCs in vitro with GM-CSF and IL-6
(referred to as BM-MDSCs) to visualize their recruitment and fate after adoptive transfer in
breast tumor-bearing mice using optical imaging (OI). OI provides only 2D planar
acquisitions with low penetration depths and distinct limitations. However, with near infrared dyes
such as DiD it is possible to achieve a high sensitivity and increase the penetration depth,
making it a powerful non-invasive imaging modality for cell tracking analyses [
]. In this study,
we show that BM-MDSCs can be stably labeled with DiD and tracked in vivo by OI, and
relocalized and characterized ex vivo by flow cytometry, allowing investigation of the localization
and fate of DiD-labeled BM-MDSCs in breast tumor-bearing mice, as a novel method for
identifying the organ-specific changes rendered to MDSCs in breast cancer.
2 / 18
Materials and methods
C57Bl/6 mice were purchased from the Walter and Eliza Hall Institute (Melbourne, Australia)
or Charles River Laboratories (Sulzfeld, Germany) with female mice used at 8±14 weeks of age.
Transgenic polyoma middle-T mouse mammary tumor virus (PyMT-MMTV) mice were
generated as described [
]. OT-I mice [
] were a kind gift from the Smyth laboratory (QIMR
Berghofer Medical Research Institute, Australia). All animal procedures were conducted in
accordance with Australian and German National Health and Medical Research regulations
on the use and care of experimental animals, and approved by the QIMR Berghofer Animal
Ethics Committee (A1212-617N) and the RegierungspraÈsidium TuÈbingen, respectively.
Animal condition (appearance, weight loss, ruffled fur, reduced mobility and body posture) was
monitored every second day throughout all experiments to ensure animal well-being and used
as humane endpoints if required. Mice were sacrificed by a chemical method (overdose of a
barbiturate anesthetic) with a secondary physical method (cervical dislocation). No animals
were euthanized prematurely in this study and all mice met criteria for euthanasia based on
The wildtype PyMT(-WT) and luciferase positive (Luc)-PyMT mammary tumor cell lines
were established, derived and maintained as previously described [
]. The lines were
authenticated as mouse lines by STR profiling (conducted every 6 months by QIMR Berghofer
core facility, last test results 7 December 2016) and confirmed to be mycoplasma free
(conducted every 4 months and when cells taken from storage by QIMR Berghofer core facility,
last test results 7 December 2016).
The generation of in vitro bone marrow-derived MDSCs (BM-MDSCs) was adapted from
Marigo et al [
]. BMDCs were flushed from the femur and tibia of mice and cultured for 5
days in ultra-low attachment petri dishes (Corning) with complete RPMI medium
supplemented with β2-mercaptoethanol and 40 ng/ml GM-CSF and IL-6 (Peprotech) on day 1, 3 and
5. On day 6, BMDCs positive for CD11b, Ly6C and Ly6G (classified as BM-MDSCs) were
obtained by Fluorescence Activated Cell Sorting (FACS) as described below and used for
Cell labeling and viability
Sorted BM-MDSCs were labeled with Vybrant1 DiD cell-labeling solution (Life
Technologies) according to manufacturer's instructions.
Antigen-specific T cell proliferation assay
CD8+ T cells were isolated by FACS from the spleen and lymph nodes of OT-I mice and
labeled with Carboxyfluorescein Diacetate Succinimidyl Ester (CFSE; Sigma) according to the
manufacturer's instructions. For co-culture, 1x105 CFSE-labeled CD8+ T cells were cultured
with 1x105 irradiated splenocytes (50 Gy for 30 minutes) from naïve C57Bl/6 mice pulsed with
SIINFEKL peptide (f.c.1 μM; Sigma) for 2 hours at room temperature. SIINFEKL is a MHC
class I-restricted peptide epitope of ovalbumin (OVA) that can be used to detect an
OVA-specific CD8+ cytolytic T cell response in cells derived from OT-I mice. BM-MDSCs (generated
3 / 18
as above) were added at various ratios as indicated and incubated for 72 hours at 37ÊC.
Proliferation of CD8+ T cells was assessed by flow cytometry as described below.
In vitro cultured BM-MDSCs and G-MDSCs (CD11b+/Ly6Cmed/Ly6G+) isolated from the
tumor, lung and spleen of PyMT-WT breast cancer-bearing and naive C57Bl/6 mice were
homogenized in lysis buffer (peqGOLD Total RNA Kit, Peqlab) directly after magnetic cell
sorting with the G-MDSC-kit (Miltenyi). Genomic DNA was digested during RNA
preparation (PeqGOLD DNase I digest kit, Peqlab) and 1 μg of RNA was transcribed into cDNA
(Superscript II Reverse Transcriptase; Invitrogen). Real-time PCR was performed in a reaction
volume of 10 μL with 20 ng cDNA, 5 pmol of the respective primers and a SYBR Green master
mix preparation (QuantiFast SYBR Green PCR Kit, Qiagen) using a LightCycler Real-Time
PCR system (Roche Diagnostics) with the following cycling conditions: 95ÊC, 15 min; 95ÊC,
15 sec; 62ÊC, 45 sec; 72ÊC, 30 sec. For mRNA expression level analysis, all investigated genes
were normalized to the housekeeping gene aldolase and CD11b/Ly6Cmed/Ly6G+ cells from the
spleens of naïve mice using the ΔΔCT method. Primer sequences listed in S1 Table.
For primary tumor growth, mice were orthotopically injected with 5x105 PyMT-WT or
LucPyMT mammary tumor cells resuspended in 20 μl PBS into the 4th left mammary fat pad
(MFP) under anesthetic. Tumor growth was monitored every 2±3 days using digital calipers.
For survival experiments, mice were euthanized at experimental endstage defined as a total
tumor volume of 525 mm3 (calculated as π x length x width2/6).
To assess metastatic tumor growth, 2.5x105 Luc-PyMT cells resuspended in 100 uL PBS
were injected intracardiacally under anesthetic. Metastatic tumor growth was monitored by
OI imaging for bioluminescent signals. Mice were euthanized at experimental endpoint (5
weeks after tumor cell injection).
BM-MDSC adoptive transfer
For adoptive transfer of BM-MDSCs, 1x106 or 4x106 DiD-labeled or unlabeled BM-MDSCs
were injected in 100 μl PBS into mice via intravenous (i.v.; tail vein) in C57Bl/6 mice bearing
PyMT-WT or Luc-PyMT primary and metastatic tumors at indicated timepoints, or via
intraperitoneal (i.p.) or intracardiac (i.c.) injections in naive C57Bl/6 mice.
Mice were injected with 150 mg/kg Luciferin (Perkin Elmer) i.p. for bioluminescence (BL)
scans. After a 2 minute uptake period, fluorescence (FL; to visualize BM-MDSCs) and BL (to
visualize tumor burden) scans were carried out on an Ivis Spectrum OI system (Perkin Elmer).
BL scans were acquired for 20, 60 and 120 seconds and signals were normalized for the photon
radiance (photons/second/cm2/sr). DiD-FL scans were acquired for 1 and 2 seconds with a
640nm excitation and 680nm emission filter and normalized for the radiant efficiency
[(photons/second/cm2/sr)/mW x cm2]. OI scans were carried out at timepoints indicated and were
analyzed using Living Image Software 4 (Perkin Elmer). Regions of interest were drawn on
target organs and background areas in ex vivo OI scans to acquire mean values for the calculation
4 / 18
Tumors and lungs were cut into small pieces and digested with 0.2 mg/mL collagenase type IV
(Worthington Biochemical Corp.) and 0.02 mg/mL DNase I (Roche) at 37ÊC for 45 min and
30 min respectively. Single cell suspensions of lung, spleen, tumor or BM-MDSCs were stained
with relevant anti-mouse antibodies in the presence of anti-CD16/32 to block Fc-receptors on
ice. Non-viable cells were excluded on the basis of staining with 7-aminoactinomycin or
Zombie Yellow (BioLegend). Flow cytometry acquisition and sorting were carried out on a FACS
Fortessa 4 and Aria II (BD Biosciences) respectively. Data analysis was performed using
FlowJo software (Tree Star). Antibody details listed in S2 Table.
Myeloid cells isolated by FACS from the tumor, lung and spleen were resuspended at 2x105
cells/mL in PBS and spun onto slides using a Cytospin 3 centrifuge (Shandon) at 500 rpm for 5
minutes. Slides were Diff-Quick stained the next day and images taken using a Leica DMIRB
microscope with NIS Elements software.
Results are expressed as mean ± SEM and analyzed by one-way ANOVA with Tukey's multiple
comparison test for significance. Kaplan-Meier Survival curves were analyzed using Log-rank
(Mantel-Cox) Tests; p values <0.05 were considered significant ( p<0.0001, p<0.001,
p<0.01 and p<0.05).
BM-MDSCs generated in vitro share similar properties with G-MDSCs
from tumor-bearing mice
Treatment of BMDCs with GM-CSF and IL-6 (Fig 1A) resulted in the expansion of a
population of myeloid cells sharing similarities with MDSCs as described [
]. We decided to focus
specifically on the G-MDSC-like population of BM-MDSCs, as this is the predominant
population in tumor-bearing mice and humans [
]. Furthermore, previous work from our lab
had shown that CD11b+/Ly6Cmed/Ly6G+ G-MDSCs were important in creating an
immunesuppressed pre-metastatic niche in breast cancer [
]. Therefore, we isolated the CD11b+/
Ly6C+/Ly6G+ fraction (BM-MDSCs) by flow cytometry (Fig 1A) for all further experiments.
This fraction demonstrated the distinct multi-lobed nuclear morphology associated with
G-MDSCs, compared to the mixed population of myeloid precursors and blast cells present
before sorting (Fig 1B). In order to determine how closely these BM-MDSCs resembled their
counterparts in tumor-bearing mice, we analyzed G-MDSCs from the spleen, lungs and
tumors of PyMT-MMTV mice that develop tumors spontaneously in the mammary fat pad,
for the expression of various cell surface receptors, and compared this with BM-MDSCs
generated with GM-CSF and IL-6 in vitro (Fig 1C). While BM-MDSCs did not demonstrate the
distinct intermediate and high Ly6C+ populations present in other organs, the CD11b+/Ly6C+/
Ly6G+ fraction showed similarly low levels of F4/80, MHC Class II and CD11c, and increased
CD115 expression (Fig 1C). All G-MDSCs expressed CD62L, CD80 and CD86 in varying
degrees, with BM-MDSCs demonstrating the highest expression of these receptors. We next
wanted to characterize the suppressive functions of these in vitro generated-BM-MDSCs. In
order to do this, we first assessed the ability of BM-MDSCs to suppress proliferation of
antigen-specific CD8+ T cells, by co-culturing BM-MDSCs at various ratios with CFSE-labeled
CD8+ T cells isolated from OT-I mice, and SIINFEKL peptide-pulsed irradiated splenocytes.
5 / 18
Fig 1. Characterization of in vitro-cultured BM-MDSCs. A) Schematic of in vitro BM-MDSC generation. BMDCs
flushed from the femur and tibia of naïve C57Bl/6 mice were cultured with IL-6 and GM-CSF for 5 days and isolated
by FACS based on CD11b+/Ly6C+/Ly6G+ expression. B) Representative Diff-Quick stained cytospin images of
CD11b+/Ly6C+/Ly6G+ cells. Images show in vitro-cultured BMDCs before FACS (left; unsorted), BM-MDSCs after
FACS (middle; sorted) and DiD-labeling (right). Images were taken at 60x magnification. C) Gating strategy and
characterization of in vitro cultured CD11b+/Ly6C+/Ly6G+ BM-MDSCs (top row) and CD11b+/Ly6Cmed/Ly6G+
G-MDSCs isolated by FACS from the lung (second row), spleen (third row) and tumor (bottom row) of
PyMT-MMTV transgenic mice, for the expression of various surface markers by flow cytometry.
We found that BM-MDSCs could partially suppress T cell proliferation at a 1:1 ratio of
BMMDSCs to T cells, and completely at a 2:1 and 5:1 ratio (Fig 2A). We also assessed gene
expression of various factors associated with the suppressive function of MDSCs including S100A8,
S100A9, Nos3, Arg1 and Arg2 in BM-MDSCs compared to G-MDSCs from the tumor, spleen
and lungs of tumor-bearing mice (Fig 2B). We found that BM-MDSCs expressed similar levels
of S100A9, Nos3 and Arg2 compared to splenic G-MDSCs (Fig 2B), but that there were
notable organ-specific differences in gene expression. Together, this data demonstrates that
CD11b+/Ly6C+/Ly6G+ BM-MDSCs generated using IL-6 and GM-CSF in vitro, display similar
morphological and functional properties to G-MDSCs expanded in the presence of a
mammary tumor in vivo.
DiD-labeled BM-MDSCs home to primary breast tumors in vivo
We next examined the dynamics of these BM-MDSCs in breast cancer, particularly in regards
to their localization and homing to different sites after adoptive transfer. In order to visualize
BM-MDSCs in vivo, we labeled them with DiD, a near-infrared fluorescent dye ideal for OI
studies. We found that DiD-labeling of BM-MDSCs for 2 minutes did not significantly affect
the viability of the cells after 48 hours, while longer incubation times impacted viability over
time (Fig 2C). By using different routes of administration (i.v., i.c., or i.p.) in naïve C57Bl/6
mice, we were able to visualize the accumulation of adoptively transferred DiD-BM-MDSCs
(1x106 cells) in different organs (Fig 2D and 2E and S1 Fig). Intravenous and intracardiac
injection led to an accumulation in the lung, liver, spleen and bone marrow (sternum, femur)
6 / 18
Fig 2. In vitro function and localization of BM-MDSCs in vivo. A) Representative histogram of CFSE-labeled CD8
OT-I T cells co-cultured with splenocytes and BM-MDSCs at various ratios as indicated (n = 3 in triplicate). B)
RT-PCR with fold change gene expression in G-MDSCs isolated from the tumor, spleen and lungs of PyMT-WT
tumor-bearing mice normalized to gene expression in BM-MDSCs (indicated by broken line; n = 3 in triplicate). C)
Percent viability of BM-MDSCs at 3, 24 and 48 hours after initial DiD-labeling for 2, 5 or 10 min relative to unlabeled
cells (broken line). Data represented as mean ± SEM. p<0.05; p<0.01; p<0.001. D, E) OI in vivo (D) and of ex
vivo organs (E) 7 days after i.v., i.c. or i.p. injection of 1x106 DiD-labeled BM-MDSCs into naïve mice. BM = bone
marrow, Li = liver, LN = lymph nodes, OM = omentum majus, S = spleen, T = thymus). RE = Radiant Efficiency;
R = Radiance.
after 7 days. After i.p. injection, DiD-BM-MDSCs were detected mainly in lymphoid tissues
attached to the spleen (omentum majus, minor), lymph nodes and bone marrow (sternum,
femur). We chose an i.v. route for adoptive transfer of BM-MDSCs for all further experiments,
as this route of administration resulted in the accumulation of DiD-BM-MDSCs in sites most
commonly affected by metastasis in breast cancer patients, including the bone, lung and liver.
Next, we examined if adoptively transferred DiD-BM-MDSCs would additionally home to
the primary tumor site in mice. We used Luc-PyMT breast tumor cells to contrast the BL
signal from the primary tumor with the FL signal from the DiD-BM-MDSCs. Two weeks after
Luc-PyMT cells were injected into the MFP, DiD-BM-MDSCs were adoptively transferred (i.
v.) into these mice and OI carried out 48 hours and 7 days later (Fig 3A). Within 48 hours after
DiD-BM-MDSC administration (day 16), a FL signal was detected which overlayed with the
BL signal from the primary tumor (Fig 3B), indicating homing of DiD-BM-MDSCs to the
tumor. This co-localization was still detectable in vivo 7 days after adoptive transfer (Fig 3C).
Ex vivo OI (Fig 3D and S1 Fig) confirmed homing of DiD-BM-MDSCs to various organs at
day 7 after adoptive transfer as in Fig 2D and 2E; with the strongest signals detected in the
tumor, lung and liver. This data demonstrates that BM-MDSCs home to the primary tumor
and accumulate in various organs after adoptive transfer.
DiD-labeled BM-MDSCs home to established metastatic tumors in vivo
Given that adoptively transferred BM-MDSCs could home to primary breast tumors, we next
wanted to determine whether the same would also occur in the context of established
metastatic lesions. As spontaneous metastasis rarely occurs after injection of PyMT-WT cells in the
MFP in this model, we injected Luc-PyMT cells i.c. and three weeks later, once metastatic
tumors were confirmed to be present by OI (Fig 4A), DiD-BM-MDSCs were adoptively
7 / 18
Fig 3. DiD-BM-MDSCs home to the primary breast tumor after adoptive transfer. A) Schematic of treatment
regimen for localization of DiD-BM-MDSCs in tumor-bearing mice. Mice were injected with 2.5x105 Luc-PyMT cells
into the MFP on day 0, and i.v. injected with 1x106 DiD-BM-MDSCs on day 14. In vivo optical images were obtained
at 48 hours (day 16) and 7 days (day 21) post-injection of DiD-BM-MDSCs. Ex vivo images were taken at 7 days
postinjection (day 21). B) Representative in vivo FL and BL optical images on day 16; 48 hours after injection of
DiD-BM-MDSCs. Tumors outlined by broken white line. C) Representative in vivo FL and BL optical images of mice
from (A) on day 21; 7 days after injection of DiD-BM-MDSCs. Treatment groups include mice with Luc-PyMT
tumors and adoptively transferred DiD-BM-MDSCs (mice 1±2; left), Luc-PyMT tumors alone (mice 3±4; middle) or
DiD-BM-MDSCs alone (mouse 5; right). Tumors outlined by broken white line. D) Representative ex vivo FL and BL
optical images of Luc-PyMT tumor-bearing mice (left) and individual organs (right) on day 21; 7 days after
DiD-BM-MDSCs injection. Tumor indicated by red arrow. BM = bone marrow, H = heart, I = intestine, Ki = kidney,
Li = liver, LN = lymph nodes, Lu = lungs, S = spleen, T = tumor. RE = Radiant Efficiency; R = Radiance.
transferred (i.v.) into these mice. In ex vivo OI measurements, we could track the
DiD-BMMDSC signal to adrenal gland metastases 2 weeks after adoptive transfer (Fig 4B). FL-signals
of DiD-BM-MDSCs (1.27x1010±1.25x109 Radiant Efficiency, RE) in adrenal gland metastases
were increased 1.8-fold over FL-signals of control animals (DiD-BM-MDSCs alone: 6.88x109±
2.76x109 RE; Luc-PyMT alone: 7.39x109±9.83x108 RE). We could also observe a 2.4-fold
increase in the DiD-BM-MDSC signal in the spleens of metastases-bearing animals (1.24x1010±
1.27x109 RE) compared to animals receiving DiD-BM-MDSCs alone (5.19x109±2.15x109 RE;
Fig 4C) but not in the lungs or liver (S2 Fig). This suggests preferential localization of
BMMDSCs to the spleen in tumor-bearing compared to tumor-free animals, even though no BL
signal was detected in the spleen (Fig 4C). Together, this data demonstrates that adoptively
transferred DiD-BM-MDSCs can home to the sites of primary and metastatic tumors, and
additionally accumulate in the spleens of tumor-bearing animals.
Adoptive transfer of DiD-BM-MDSCs does not alter primary breast tumor
As these BM-MDSCs were shown to demonstrate suppressive properties (Fig 2A and 2B), we
next wanted to investigate whether the accumulation of BM-MDSCs in the primary tumor
impacted growth. We examined this in two different ways. First, mice bearing PyMT-WT
tumors were i.v. injected with two doses of either 1x106 or 4x106 BM-MDSCs at day 10 and 20
after tumor cell injection, and primary tumor growth monitored to endstage (S3 Fig). In both
cases, adoptive transfer of BM-MDSCs into tumor-bearing mice did not impact tumor growth
or overall survival compared to control tumor-bearing mice (S3 Fig). Therefore, although we
8 / 18
Fig 4. Homing of adoptively transferred DiD-BM-MDSCs to established metastases. A) Representative in vivo
images of Luc-PyMT metastases (BL signal) 3 weeks after i.c. injection into C57Bl/6 mice. B) Representative ex vivo
images of DiD-BM-MDSC (FL signal; top panel) localization to adrenal gland metastases (BL signal; bottom panel).
DiD-BM-MDSCs were injected (i.v.) into mice from A, and images acquired 2 weeks later. Quantification of radiant
efficiency (RE) of FL-signal for the adrenal gland shown on the right. C) Representative images of spleens (left) and RE
quantification (right) from treatment groups described in A and B. Naïve C57Bl/6 mice were used as controls. Data
represented as mean ± SEM; p<0.05; p<0.001; n = 3±5 mice for all groups.
found that adoptively transferred BM-MDSCs home to the primary tumor site (Fig 2), these
BM-MDSCs did not affect their growth.
Secondly, we examined whether the presence of BM-MDSCs at the initiation of tumor
development would affect the growth kinetics of the primary tumor. To do this, BM-MDSCs
were co-injected with PyMT-WT tumor cells at a ratio of 1:1 into the mammary fat pad and
tumor growth monitored. However, no differences in tumor growth or overall survival were
observed compared to mice injected with PyMT-WT cells alone (S4 Fig). Therefore although
BM-MDSCs were able to suppress T cell function in vitro, this did not translate into an effect
on tumor growth in vivo. This data is in accordance with previously published studies,
demonstrating that CD11b+/Gr1high MDSCs are the least suppressive subpopulation of MDSCs and
do not inhibit breast tumor growth after adoptive transfer in vivo [
Changes in the breast tumor microenvironment after BM-MDSC adoptive
As DiD-BM-MDSCs were shown to home to but not affect the growth of primary breast
tumors, we next wanted to analyze the composition of the TME relative to control mice.
Similar to the homing experiments in Fig 3, mice were injected with 1x106 DiD-BM-MDSCs on
days 10 and 20 after PyMT-WT tumor cell injection into the MFP (S5 Fig). Mice were
sacrificed 48 hours (day 22), 5 days (day 25) or 7 days (day 27) after the second DiD-BM-MDSC
injection and tumors, lungs and spleen harvested and analyzed by flow cytometry for different
Within the TME, we observed a significant decrease in the overall frequency of CD3+
lymphocytes at 48 hours and 7 days after DiD-BM-MDSC injection compared to tumor-bearing
controls (S5 Fig). After 48 hours, we also observed a significant increase in the frequency of
9 / 18
Ly6C+ cells within the CD11b+ myeloid population in the primary tumor (S5 Fig); however
this was not detectable at day 7. When we focused on the MHC II+/CD45.2+ myeloid
populations in particular, we found that generally, the frequency of macrophages (CD11b+/F480+)
and DCs (CD11c+) was increased after 48 hours compared to controls, but that these
differences were not apparent at day 7 (S5 Fig). Therefore, adoptive transfer of BM-MDSCs
appeared to alter the TME within 48 hours after injection, however, most of these changes
were undetectable by day 7.
We also analyzed the same populations in the spleen and lungs of these mice at 48 hours
and 5 days after injection. Interestingly, the dynamics of the cell populations appeared to be
organ-dependent. In the spleen at 48 hours, no changes in lymphocytes were observed, but
Ly6C+ and F480+ populations of CD11b+ cells were decreased (S6 Fig). However, most of
these changes were not apparent after 5 days. In the lungs, we did not observe any significant
changes to any cell populations after 48 hours or 5 days (S6 Fig).
The fate of adoptively transferred DiD-BM-MDSCs is dictated by the local
While accumulation of adoptively transferred BM-MDSCs might be expected to alter the local
organ environment as described above, similarly, the local environment could also impact
BM-MDSCs. Given the importance of tumor-derived factors on MDSC mobilization and
function, we reasoned that microenvironmental influences may either maintain the
BMMDSCs in an immature state or promote their differentiation into mature myeloid
populations. Therefore, in order to track the fate of these BM-MDSCs in specific organs after adoptive
transfer, we utilized the DiD fluorescence signal to examine BM-MDSCs ex vivo by flow
From the above experiments, we were able to conclude that the most significant changes to
local organ environments were apparent within 48 hours after adoptive transfer of
BMMDSCs. Furthermore, we were confident that these cells remained viable at this time point
based on our in vitro viability studies (Fig 2). Therefore, in order to better visualize and analyze
the fate of DiD-BM-MDSCs, we adoptively transferred two doses of 4x106 DiD-BM-MDSCs
(total of 8x106 cells) and conducted flow cytometry analysis at the 48-hour timepoint (Fig 5A).
DiD-BM-MDSC dosing was adjusted to days 11 and 22 and flow cytometry performed on day
24 to ensure similar primary tumor sizes (at BM-MDSC dosing) compared to previous
experiments. Adoptive transfer of 8x106 DiD-BM-MDSCs did not impact tumor growth or weight
(Fig 5B), and given the lack of stromal cell changes previously observed in the lung, we focused
on the primary tumor and spleen for further analysis.
Again when we analyzed the overall changes within the TME, CD3+ lymphocytes were
decreased after adoptive transfer of DiD-BM-MDSCs compared to controls (Fig 5C), but this
time specifically in regards to CD8+ T cells. CD4+ T cells, Natural Killer (NK) cells and
Regulatory T cells (Tregs) were unchanged (Fig 5C and 5D). Of the general myeloid populations,
only CD11b+/Ly6Cmed/Ly6G+ cells were increased (Fig 5E), while DCs and macrophages
remained unchanged (Fig 5F). Within the CD11b+/Ly6C+ subset however, we observed a
distinct CD11b+/Ly6Clo population that was significantly increased in the primary tumor after
DiD-BM-MDSC injection (Fig 5G and 5H). Interestingly, these changes were not observed in
the myeloid cell populations in the spleens of these mice (S7 Fig).
We then focused our analysis on the DiD+ population (detected as Cy5 by flow cytometry)
of CD45+ cells (CD45+/Cy5+) at day 24 (Fig 6A) to determine the specific fate of the adoptively
transferred DiD-BM-MDSCs. In the primary tumor, very few CD11b/Ly6Cmed/Ly6G+ cells
(1.1±0.2%) could be detected relative to CD11b/Ly6Chi/Ly6G- cells (19.7±1.9%) (Fig 6B).
10 / 18
Fig 5. Breast tumor microenvironment dynamics after adoptive transfer of DiD-BM-MDSCs. A) Schematic of
treatment regimen for TME analysis after adoptive transfer of DiD-BM-MDSCs into tumor-bearing mice. Mice were
injected with PyMT-WT cells into the MFP on day 0, and i.v. injected with 4x106 DiD-BM-MDSCs on day 11 and 22.
Tumors were analyzed by flow cytometry 48 hours (day 24) after the second dose of DiD-BM-MDSCs. PyMT-WT
tumor-bearing mice were used as controls (control n = 5; DiD-BM-MDSC n = 6 for all analyses). B) Tumor weight at
time of flow cytometry analysis at day 24. C) Flow cytometry analysis of CD3 lymphocytes, CD3/CD4 and CD3/CD8 T
cells, as well as CD3-/NK1.1+ NK cells within the tumor at day 24. D) Flow cytometry analysis of the percentage of
Foxp3+ cells within the CD3/CD4 T cell population at day 24. E) Flow cytometry analysis of CD11b/Ly6C/Ly6G
myeloid populations as a percentage of CD45.2+ cells within the tumor at day 24. F) Flow cytometry analysis of DCs
(CD11c/MHC Class II) and macrophages (CD11b/F480/MHC Class II) as a percentage of CD45.2+ cells within the
tumor at day 24. G) Representative flow cytometry plots of CD11b/Ly6C populations (hi = high, med = medium and
lo = low) within the CD45.2+ population in the tumor at day 24 and quantified in H. Data represented as mean ± SEM.
p<0.05; n.s. not significant.
Within the Cy5+-Ly6C populations however, although Ly6Cmed cells were the predominant
population (47.3±4.4%), both Ly6Chi (19.9±1.8%) and Ly6Clo (22.8±1.1%) cells were also
present (Fig 6C). Given the spread of Ly6Chi, Ly6Cmed and Ly6Clo cells observed, we also analyzed
mature myeloid populations to determine if the adoptively transferred DiD-BM-MDSCs may
have differentiated within the TME. Within the CD45/Cy5+-population, DCs made up more
than half of the population (54.4±1.9%), followed by macrophages (25.4±1.8%) and
granulocytes (3.3±0.4%) (Fig 6D), suggesting preferential differentiation of DiD-BM-MDSCs to DCs
and macrophages within the tumor.
These changes were not observed in spleen however, with CD11b/Ly6Cmed/Ly6G+ and
CD11b/Ly6Chi/Ly6G- cells making up only a very small percentage of the overall CD45/Cy5+
population (1.2±0.3% and 1.3±0.2% respectively) (Fig 6E and 6F). This was also observed in the
proportion of Ly6Chi (1.3±0.2%), Ly6Cmed (2.6±0.4%) and Ly6Clo (3.1±0.3%) cells within the
CD45/Cy5+ population (Fig 6G). DCs were again the most prominent of the mature myeloid
populations (2.5±0.1%) compared to macrophages (1.8±0.2%) and granulocytes (1.3±0.3%)
(Fig 6H). However the frequency of these mature myeloid populations within the Cy5+
population was negligible. Taken together, this data suggests that the local environment within
particular organs play a crucial role in dictating the fate of adoptively transferred BM-MDSCs in vivo.
In this study, we show that BM-MDSCs generated in vitro using BMDCs treated with IL-6 and
GM-CSF, show similar morphological and functional properties to G-MDSCs from breast
11 / 18
Fig 6. Fate of adoptively transferred DiD-BM-MDSC in the tumor and spleen of breast tumor-bearing mice. A)
Representative flow cytometry plots of the CD45.2/DiD-Cy5+ gated population in PyMT-WT tumors from control
mice (primary tumor alone; left) and after adoptive transfer of DiD-BM-MDSCs (right) on day 24 as in Fig 5B and 5C)
Flow cytometry analysis of CD11b/Ly6C/Ly6G (B) and CD11b/Ly6C subpopulations (C) as a percentage of CD45/
Cy5+ cells within the tumor. D) Flow cytometry analysis of mature myeloid populations including granulocytes
(CD11b/Ly6G), macrophages and DCs as a percentage of CD45/Cy5+ cells within the tumor. E) Representative flow
cytometry plots of the CD45.2/DiD-Cy5+ gated population within the spleen of PyMT-WT tumor-bearing mice
(control; left) and after adoptive transfer of DiD-BM-MDSCs (right). F,G) Flow cytometry analysis of CD11b/Ly6C/
Ly6G (F) and CD11b/Ly6C subpopulations (G) as a percentage of CD45/Cy5+ cells within the spleen. H) Flow
cytometry analysis of mature myeloid populations including granulocytes, macrophages and DCs as a percentage of
CD45/Cy5+ cells within the spleen. Data represented as mean ± SEM; n = 6 for all groups.
tumor-bearing mice. Furthermore that fluorescent labeling of these BM-MDSCs allows us to
track their homing and localization after adoptive transfer through OI, and determine their
fate ex vivo through flow cytometry. Here we demonstrate, for the first time, that these
adoptively transferred BM-MDSCs are actively recruited to tumor sites (primary or metastatic)
where they are incorporated into the TME. After i.v. administration into naïve mice,
DiD-BM-MDSCs were only shown to accumulate in the lung, liver and spleen. In
tumor-bearing mice however, DiD-BM-MDSCs co-localized to the primary tumor and with metastatic
tumors in the adrenal gland. This data is in accordance with previous studies showing that
MDSCs actively migrate to tumor sites [
]. Although accumulation of BM-MDSCs did not
affect primary tumor growth, even after adoptive transfer of 8x106 cells, this finding is
consistent with previous studies in which adoptively transferred G-MDSCs were found to be poorly
immunosuppressive in vivo and failed to prevent tumor growth even in high numbers [
Accumulation of DiD-BM-MDSCs in tumor-bearing mice was not just limited to the sites
of tumor growth. DiD-BM-MDSCs were also increased in the spleens of tumor-bearing mice
compared to cancer-free controls. MDSCs display functional differences and varied
mechanisms of suppression depending on their location at the primary tumor or peripheral sites
]. Accordingly, we observed differences in expression of various genes associated with
the suppressive function of MDSCs, based on tissue of origin. Additionally, we demonstrated
that the adoptive transfer of DiD-BM-MDSCs into tumor-bearing mice induces distinct
changes to the composition of the local microenvironment, as well as the fate of the
DiD-BMMDSCs in the spleen and tumor.
MDSCs rely on various tumor-derived cytokines and growth factors for their mobilization,
expansion, polarization and immunosuppressive function (reviewed in [
]). Indeed recent
studies indicate that the TME can directly alter the properties of MDSCs and subsequently
12 / 18
their function. For example, GM-CSF within the TME has been shown to expand Gr1int
MDSCs (M-MDSC; Ly6Chi equivalent), as well as a Gr1lo (Ly6Clo equivalent) fraction [
In this study, BM-MDSCs generated in vitro were morphologically similar to G-MDSCs (from
tumor-bearing mice) and were able to suppress antigen-specific T cell proliferation, consistent
with previous reports . Ex vivo flow cytometry of these DiD-BM-MDSCs after adoptive
transfer however, demonstrated that very few remained as CD11b/Ly6C+/Ly6G+ cells in the
tumor, spleen or lung.
In the tumor, almost 20% of the DiD+ (Cy5+) population resembled M-MDSCs in regards
to cell surface receptor expression (CD11b/Ly6Chi/Ly6G-), with Ly6G expression mostly
absent. As only CD11b/Ly6C+/Ly6G+ BM-MDSCs with a polymorphonuclear morphology
were adoptively transferred into mice, this suggests some of kind of plasticity within the
M-MDSC and G-MDSC populations. Whether MDSCs can switch between the monocytic
and granulocytic fractions is controversial, with G-MDSCs believed to be terminally
]. However, Ly6Chi, Ly6Cmed and a distinct Ly6Clo subset were evident within the
tumor-derived DiD-Cy5+ population 48 hours after adoptive transfer, suggesting
differentiation of BM-MDSCs into other myeloid cell subsets. Furthermore, this apparent switch to
M-MDSC-like cells within the TME is important, as G-MDSCs are thought to be terminally
differentiated with only M-MDSCs reported to differentiate into macrophages and DCs [
The increased proportion of DCs and macrophages within the DiD-Cy5+ population might be
reflective of differentiation of M-MDSCs within the TME. In support of this, M-MDSCs
recruited to tumors have been demonstrated to rapidly differentiate into immunosuppressive
macrophages and DCs (whose suppressive nature is still unknown) in the presence of
tumorderived soluble factors [
]. In our studies, whether the resulting DiD-Cy5+
macrophages and DCs are immunosuppressive remains to be investigated. However, recent work
has shown that MDSCs can be reprogrammed by the TME to become tolerogenic DCs .
While further characterization of the DiD-Cy5+ DC population would need to be carried out,
the distinct CD11b/Ly6Clo population only evident in the tumor after DiD-BM-MDSC
adoptive transfer suggests this may be an important avenue of investigation. Taken together, our
data suggests that factors within the primary breast TME potentially promote differentiation
of adoptively transferred BM-MDSCs into M-MDSCs, as well as macrophages and DCs.
In this study, we have also developed a tool that will allow us to address these additional
questions. The in vitro generation of BM-MDSCs and ability to detect them through OI and
flow cytometry once labeled with DiD, provide opportunities to interrogate this dynamic
interaction of MDSCs within the TME as well as the local environments of other organs in the
shortterm. Although lipophilic dyes such as DiD are described to stably incorporate into the cell
membrane and be transferred to daughter cells alone [
], contamination to neighboring cells
has been reported [
]. We found that BM-MDSCs generated from the bone marrow of eGFP
C57Bl/6 mice were not sufficiently detectable by flow cytometry within the tumor, due to high
background signals and autofluorescence. Therefore in future studies requiring long-term
evaluation of BM-MDSC tracking and fate, it may be useful to develop alternative methods of cell
labeling. Other approaches include radioactive cell labeling using [64Cu]PTSM or 64Cu-labeled
monoclonal antibodies for quantitative positron emission tomography (PET) and iron oxide
labeling, or 19F-labeling for magnetic resonance imaging (MRI) [45±47]. Combined PET/MRI
is superior to OI as it enables holistic three-dimensional whole body tracking, which would
allow visualization of BM-MDSCs for longer time periods and at higher resolution.
Co-localization of BM-MDSCs within different tumor regions, e.g. necrotic centers, areas of angiogenesis,
invasive growth areas, is possible using adequate imaging technology and would enable the
detailed characterization of the homing patterns of BM-MDSCs. Moving forward, it would be
interesting to isolate the M-MDSC-like fraction of BM-MDSCs (CD11b/Ly6Chi/Ly6G-) and
13 / 18
compare and contrast their homing, localization, plasticity and differentiation in breast
tumorbearing mice and other cancer types. Furthermore, very little is known regarding the
involvement of MDSCs in metastatic tumor microenvironments and for example, in the formation of
pre-metastatic niches, in which they have been reported to accumulate and promote metastatic
breast tumor outgrowth [
]. Determining how MDSC differentiation and function is affected
within different tumor microenvironments may also help to identify novel methods of
therapeutic intervention, thereby enabling targeting of MDSCs to reduce immunosuppression.
S1 Table. Primer sequences for RT-PCR.
S2 Table. Monoclonal anti-mouse antibody details used for flow cytometry.
S1 Fig. Quantification of DiD-BM-MDSC accumulation in ex vivo organs. A)
Quantification of radiant efficiency of FL-signal for ex vivo lung, liver and spleen 7 days after i.v., i.c. or i.
p. injection of 1x106 DiD-labeled BM-MDSCs into naïve mice as shown in Fig 2E. B)
Quantification of radiant efficiency of FL-signal for ex vivo lung, liver, spleen and tumor from
LucPyMT tumor-bearing mice on day 21; 7 days after DiD-BM-MDSCs injection from Fig 3D.
Data represented as mean ± SEM; n = 3±5 mice for all groups.
S2 Fig. DiD-BM-MDSCs do not home to lungs or liver in mice with established metastases.
A-B) Representative ex vivo images of DiD-BM-MDSC (FL signal; top panel) localization to liver
(A) and lung (B) 2 weeks after i.v. injection of DiD-BM-MDSCs into mice with metastatic tumors
(BL signal; bottom panel) from Fig 4. Quantification of radiant efficiency (RE) of FL-signal shown
on the right. Naïve C57Bl/6 mice were used as controls. Data represented as mean ± SEM;
p<0.05; p<0.001; n = 3±5 mice for all groups. RE = Radiant Efficiency; R = Radiance.
S3 Fig. Adoptive transfer of BM-MDSCs does not alter primary tumor growth. A)
Schematic of treatment regimen for survival analysis after adoptive transfer of BM-MDSCs into
tumor-bearing mice. Mice were orthotopically injected with 5x105 PyMT-WT cells into the
MFP on day 0, and i.v. injected with 1x106 or 4x106 BM-MDSCs on day 10 and 20. Primary
tumor growth was monitored to endstage. B,C) Individual tumor growth curves (B) and
Kaplan-Meier survival curves (C) after i.v. injection of 1x106 BM-MDSCs at day 10 and 20
(primary tumor n = 5; primary tumor + BM-MDSCs n = 10). D,E) Individual tumor growth
curves (D) and Kaplan-Meier survival curve (E) for mice injected with 4x106 BM-MDSCs on
day 10 and day 20 (primary tumor alone n = 5; primary tumor + BM-MDSCs n = 6).
S4 Fig. Co-injection of BM-MDSCs does not alter primary tumor growth. A,B) Individual
tumor growth curves (A) and Kaplan-Meier survival curve (B) for mice injected with 5x105
PyMT-WT tumor cells alone (primary tumor n = 5) or co-injected with 5x105 BM-MDSCs in
the mammary fat pad (primary tumor + BM-MDSCs n = 7).
S5 Fig. Tumor microenvironment dynamics after adoptive transfer of BM-MDSCs. A)
Schematic of treatment regimen for tumor microenvironment analysis after adoptive transfer
of DiD-BM-MDSCs into tumor-bearing mice. Mice were orthotopically injected with 5x105
14 / 18
PyMT-WT cells into the MFP on day 0, and i.v. injected with 1x106 DiD-BM-MDSCs on day
10 and 20. Tumors and organs were harvested and analyzed by flow cytometry at 48 hours
(day 22) or 7 days (day 27) after the second BM-MDSC injection. Tumors from mice injected
with PyMT-WT cells alone were used as controls. B-D) Flow cytometry analysis of CD3
lymphocyte populations (B) as a percentage of CD45.2, Ly6C and Ly6G myeloid cell populations
(C) as a percentage of CD45.2/CD11b cells, and macrophage and dendritic cell populations
(D) as a percentage of CD45.2/MHC Class II cells within the primary tumor 48 hours (n = 4
per group) and 7 days (n = 6 per group) after second BM-MDSC injection. Data represented
as mean ± SEM. p<0.01; p<0.001.
S6 Fig. Microenvironment dynamics in the spleen and lungs after adoptive transfer of
BM-MDSCs into breast tumor-bearing mice. (A-C) Flow cytometry analysis of CD3
lymphocyte (A), CD11b myeloid (B) and macrophage and dendritic cell (C) populations within
the spleen of mice injected with 1x106 BM-MDSCs i.v. on day 10 and 20 after PyMT-WT
tumor cell injection (n = 4 for all groups). Spleens were analyzed 48 hours (day 22) and 5 days
(day 25) after second injection of BM-MDSCs. Spleens from PyMT-WT tumor-bearing mice
were used as controls. (D-F) Flow cytometry analysis of CD3 lymphocytes (D), CD11b
myeloid (E) and macrophage and dendritic populations (F) in the lungs of mice injected with
1x106 BM-MDSCs i.v. on day 10 and 20 after PyMT-WT tumor cell injection (n = 4 for all
groups). Lungs were analyzed 48 hours (day 22) and 5 days (day 25) after second injection of
BM-MDSCs. Lungs from PyMT-WT tumor-bearing mice were used as controls. Data
represented as mean ± SEM. p<0.05; p<0.01; p<0.001.
S7 Fig. Spleen microenvironment dynamics after adoptive transfer of DiD-BM-MDSCs
into tumor-bearing mice. A) Flow cytometry analysis of CD3 lymphocytes, CD3/CD4 and
CD3/CD8 T cells, as well as CD3-/NK1.1+ NK cells from the spleen of tumor-bearing mice
(control) and after adoptive transfer of DiD-BM-MDSCs at day 24 (48 hours after second dose
of DiD-BM-MDSCs). B) Flow cytometry analysis of the percentage of Foxp3+ cells within the
CD3/CD4 T cell population in the spleen at day 24. C) Flow cytometry analysis of CD11b/
Ly6C myeloid populations as a percentage of CD45.2+ cells within the spleen at day 24. D)
Flow cytometry analysis of DCs and macrophages as a percentage of CD45.2+ cells within the
spleen at day 24. E) Representative flow cytometry plots of CD11b/Ly6C populations within
the spleen at day 24. For all analyses, control n = 5; DiD-BM-MDSC n = 6. Data represented as
mean ± SEM. p<0.05; n.s. not significant.
The authors would like to thank Melanie Becker, Daniel Bukala and Natalie Altmeyer for
experimental assistance, and Shin Foong Ngiow for valuable research input.
Conceptualization: Jaclyn Sceneay, Christoph M. Griessinger, Bernd J. Pichler, Andreas
Data curation: Christina S. F. Wong, Manfred Kneilling, Andreas MoÈller.
Formal analysis: Andreas MoÈller.
15 / 18
Funding acquisition: Bernd J. Pichler, Andreas MoÈller.
Investigation: Jaclyn Sceneay, Christoph M. Griessinger, Sabrina H. L. Hoffmann, Shu Wen
Wen, Christina S. F. Wong, Sophie Krumeich.
Methodology: Jaclyn Sceneay, Christoph M. Griessinger, Sabrina H. L. Hoffmann, Shu Wen
Wen, Christina S. F. Wong, Sophie Krumeich.
Project administration: Manfred Kneilling, Bernd J. Pichler.
Resources: Manfred Kneilling, Bernd J. Pichler, Andreas MoÈller.
Supervision: Jaclyn Sceneay, Christoph M. Griessinger, Shu Wen Wen, Christina S. F. Wong,
Manfred Kneilling, Bernd J. Pichler, Andreas MoÈller.
Validation: Jaclyn Sceneay, Sabrina H. L. Hoffmann, Shu Wen Wen, Christina S. F. Wong.
Writing ± original draft: Jaclyn Sceneay, Christoph M. Griessinger, Andreas MoÈller.
Writing ± review & editing: Jaclyn Sceneay, Christoph M. Griessinger, Sabrina H. L.
Hoffmann, Shu Wen Wen, Christina S. F. Wong, Sophie Krumeich, Manfred Kneilling, Bernd J.
Pichler, Andreas MoÈller.
16 / 18
Cancer Immunol Res. 2014; 2(7):655±67. https://doi.org/10.1158/2326-6066.CIR-13-0209 PMID:
17 / 18
1. Gabrilovich DI , Nagaraj S . Myeloid-derived suppressor cells as regulators of the immune system . Nat Rev Immunol . 2009 ; 9 ( 3 ): 162 ± 74 . https://doi.org/10.1038/nri2506 PMID: 19197294
2. Gabrilovich DI , Ostrand-Rosenberg S , Bronte V . Coordinated regulation of myeloid cells by tumours . Nat Rev Immunol . 2012 ; 12 ( 4 ): 253 ± 68 . https://doi.org/10.1038/nri3175 PMID: 22437938
3. Youn JI , Nagaraj S , Collazo M , Gabrilovich DI . Subsets of myeloid-derived suppressor cells in tumorbearing mice . J Immunol . 2008 ; 181 ( 8 ): 5791 ± 802 . PMID: 18832739
4. Diaz-Montero CM , Salem ML , Nishimura MI , Garrett-Mayer E , Cole DJ , Montero AJ . Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy . Cancer Immunol Immunother . 2009 ; 58 ( 1 ): 49 ± 59 . https://doi.org/10.1007/s00262-008 -0523-4 PMID: 18446337
5. Bronte V , Wang M , Overwijk WW , Surman DR , Pericle F , Rosenberg SA , et al. Apoptotic death of CD8 + T lymphocytes after immunization: induction of a suppressive population of Mac-1+/Gr-1+ cells . J Immunol . 1998 ; 161 ( 10 ): 5313 ± 20 . PMID: 9820504
6. Kusmartsev S , Gabrilovich DI . Immature myeloid cells and cancer-associated immune suppression . Cancer Immunol Immunother . 2002 ; 51 ( 6 ): 293 ±8. https://doi.org/10.1007/s00262-002 -0280-8 PMID: 12111117
7. Chioda M , Peranzoni E , Desantis G , Papalini F , Falisi E , Solito S , et al. Myeloid cell diversification and complexity: an old concept with new turns in oncology . Cancer Metastasis Rev . 2011 ; 30 ( 1 ): 27 ± 43 . https://doi.org/10.1007/s10555-011 -9268-1 PMID: 21267772
8. Peranzoni E , Zilio S , Marigo I , Dolcetti L , Zanovello P , Mandruzzato S , et al. Myeloid-derived suppressor cell heterogeneity and subset definition . Curr Opin Immunol . 2010 ; 22 ( 2 ): 238 ± 44 . https://doi.org/10. 1016/j.coi. 2010 . 01 .021 PMID: 20171075
9. Poschke I , Kiessling R . On the armament and appearances of human myeloid-derived suppressor cells . Clin Immunol . 2012 ; 144 ( 3 ): 250 ± 68 . https://doi.org/10.1016/j.clim. 2012 . 06 .003 PMID: 22858650
10. Movahedi K , Guilliams M , Van den Bossche J , Van den Bergh R , Gysemans C , Beschin A , et al. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cellsuppressive activity . Blood . 2008 ; 111 ( 8 ): 4233 ± 44 . https://doi.org/10.1182/blood-2007 -07-099226 PMID: 18272812
11. Dolcetti L , Peranzoni E , Ugel S , Marigo I , Fernandez Gomez A , Mesa C , et al. Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF . Eur J Immunol . 2010 ; 40 ( 1 ): 22 ± 35 . https://doi.org/10.1002/eji.200939903 PMID: 19941314
12. Hammami I , Chen J , Bronte V , DeCrescenzo G , Jolicoeur M. L-glutamine is a key parameter in the immunosuppression phenomenon . Biochem Biophys Res Commun . 2012 ; 425 ( 4 ): 724 ±9. https://doi. org/10.1016/j.bbrc. 2012 . 07 .139 PMID: 22885179
13. Elpek KG , Cremasco V , Shen H , Harvey CJ , Wucherpfennig KW , Goldstein DR , et al. The tumor microenvironment shapes lineage, transcriptional, and functional diversity of infiltrating myeloid cells .
14. Youn JI , Gabrilovich DI . The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity . Eur J Immunol . 2010 ; 40 ( 11 ): 2969 ± 75 . https://doi.org/10. 1002/eji.201040895 PMID: 21061430
15. Marigo I , Dolcetti L , Serafini P , Zanovello P , Bronte V . Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells . Immunol Rev . 2008 ; 222 : 162 ± 79 . https://doi.org/10.1111/j. 1600 - 065X . 2008 . 00602 . x PMID : 18364001
16. Sinha P , Okoro C , Foell D , Freeze HH , Ostrand-Rosenberg S , Srikrishna G . Proinflammatory S100 Proteins Regulate the Accumulation of Myeloid-Derived Suppressor Cells . The Journal of Immunology . 2008 ; 181 ( 7 ): 4666 ± 75 . PMID: 18802069
17. Bunt SK , Sinha P , Clements VK , Leips J , Ostrand-Rosenberg S . Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression . J Immunol . 2006 ; 176 ( 1 ): 284 ± 90 . PMID: 16365420
18. Gallina G , Dolcetti L , Serafini P , De Santo C , Marigo I , Colombo MP , et al. Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells . J Clin Invest . 2006 ; 116 ( 10 ): 2777 ± 90 . https://doi.org/10.1172/JCI28828 PMID: 17016559
19. Ostrand-Rosenberg S , Sinha P . Myeloid-derived suppressor cells: linking inflammation and cancer . J Immunol . 2009 ; 182 ( 8 ): 4499 ± 506 . https://doi.org/10.4049/jimmunol.0802740 PMID: 19342621
20. Shojaei F , Wu X , Qu X , Kowanetz M , Yu L , Tan M , et al. G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models . Proceedings of the National Academy of Sciences . 2009 ; 106 ( 16 ): 6742 ± 7 .
21. Morales JK , Kmieciak M , Knutson KL , Bear HD , Manjili MH . GM-CSF is one of the main breast tumorderived soluble factors involved in the differentiation of CD11b-Gr1- bone marrow progenitor cells into myeloid-derived suppressor cells . Breast Cancer Res Treat . 2010 ; 123 ( 1 ): 39 ± 49 . https://doi.org/10. 1007/s10549-009 -0622-8 PMID: 19898981
22. Shojaei F , Wu X , Zhong C , Yu L , Liang XH , Yao J , et al. Bv8 regulates myeloid-cell-dependent tumour angiogenesis . Nature . 2007 ; 450 ( 7171 ): 825 ± 31 . https://doi.org/10.1038/nature06348 PMID: 18064003
23. Huang B , Lei Z , Zhao J , Gong W , Liu J , Chen Z , et al. CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers . Cancer Letters . 2007 ; 252 ( 1 ): 86 ± 92 . https://doi.org/10.1016/j. canlet. 2006 . 12 .012 PMID: 17257744
24. Yang L , Huang J , Ren X , Gorska AE , Chytil A , Aakre M , et al. Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis . Cancer Cell . 2008 ; 13 ( 1 ): 23 ± 35 . https://doi.org/10.1016/j.ccr. 2007 . 12 .004 PMID: 18167337
25. Qin H , Lerman B , Sakamaki I , Wei G , Cha SC , Rao SS , et al. Generation of a new therapeutic peptide that depletes myeloid-derived suppressor cells in tumor-bearing mice . Nat Med . 2014 ; 20 ( 6 ): 676 ± 81 . https://doi.org/10.1038/nm.3560 PMID: 24859530
26. Iclozan C , Antonia S , Chiappori A , Chen DT , Gabrilovich D. Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer . Cancer Immunol Immunother . 2013 ; 62 ( 5 ): 909 ± 18 . https://doi.org/10.1007/s00262-013 - 1396-8 PMID: 23589106
27. Talmadge JE , Gabrilovich DI . History of myeloid-derived suppressor cells . Nat Rev Cancer . 2013 ; 13 ( 10 ): 739 ± 52 . https://doi.org/10.1038/nrc3581 PMID: 24060865
28. Youn JI , Collazo M , Shalova IN , Biswas SK , Gabrilovich DI . Characterization of the nature of granulocytic myeloid-derived suppressor cells in tumor-bearing mice . J Leukoc Biol . 2012 ; 91 ( 1 ): 167 ± 81 . https://doi.org/10.1189/jlb.0311177 PMID: 21954284
29. Marigo I , Bosio E , Solito S , Mesa C , Fernandez A , Dolcetti L , et al. Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor . Immunity . 2010 ; 32 ( 6 ): 790 ± 802 . https://doi.org/10.1016/j.immuni. 2010 . 05 .010 PMID: 20605485
30. Bayne LJ , Beatty GL , Jhala N , Clark CE , Rhim AD , Stanger BZ , et al. Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer . Cancer Cell . 2012 ; 21 ( 6 ): 822 ± 35 . https://doi.org/10.1016/j.ccr. 2012 . 04 .025 PMID: 22698406
31. Bronte V , Chappell DB , Apolloni E , Cabrelle A , Wang M , Hwu P , et al. Unopposed Production of Granulocyte-Macrophage Colony-Stimulating Factor by Tumors Inhibits CD8+ T Cell Responses by Dysregulating Antigen-Presenting Cell Maturation . The Journal of Immunology . 1999 ; 162 ( 10 ): 5728 ± 37 . PMID: 10229805
32. Serafini P , Carbley R , Noonan KA , Tan G , Bronte V , Borrello I . High-Dose Granulocyte-Macrophage Colony-Stimulating Factor-Producing Vaccines Impair the Immune Response through the Recruitment of Myeloid Suppressor Cells . Cancer Research . 2004 ; 64 ( 17 ): 6337 ± 43 . https://doi.org/10.1158/ 0008 - 5472 .CAN- 04 -0757 PMID: 15342423
33. Sutton EJ , Henning TD , Pichler BJ , Bremer C , Daldrup-Link HE . Cell tracking with optical imaging . Eur Radiol . 2008 ; 18 ( 10 ): 2021 ±32. https://doi.org/10.1007/s00330-008-0984-z PMID: 18506449
34. Wong CS , Sceneay J , House CM , Halse HM , Liu MC , George J , et al. Vascular normalization by loss of Siah2 results in increased chemotherapeutic efficacy . Cancer Res . 2012 ; 72 ( 7 ): 1694 ± 704 . https://doi. org/10.1158/ 0008 - 5472 .CAN- 11 -3310 PMID: 22354750
35. Hogquist KA , Jameson SC , Heath WR , Howard JL , Bevan MJ , Carbone FR . T cell receptor antagonist peptides induce positive selection . Cell . 1994 ; 76 ( 1 ): 17 ± 27 . PMID: 8287475
36. Sceneay J , Chow MT , Chen A , Halse HM , Wong CS , Andrews DM , et al. Primary tumor hypoxia recruits CD11b+/Ly6Cmed/Ly6G+ immune suppressor cells and compromises NK cell cytotoxicity in the premetastatic niche . Cancer Res . 2012 ; 72 ( 16 ): 3906 ± 11 . https://doi.org/10.1158/ 0008 - 5472 .CAN- 11 - 3873 PMID: 22751463
37. Kusmartsev S , Nefedova Y , Yoder D , Gabrilovich DI . Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species . J Immunol . 2004 ; 172 ( 2 ): 989 ± 99 . PMID: 14707072
38. Corzo CA , Condamine T , Lu L , Cotter MJ , Youn JI , Cheng P , et al. HIF -1alpha regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment . J Exp Med . 2010 ; 207 ( 11 ): 2439 ± 53 . https://doi.org/10.1084/jem.20100587 PMID: 20876310
39. Kumar V , Patel S , Tcyganov E , Gabrilovich DI . The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment . Trends Immunol . 2016 ; 37 ( 3 ): 208 ± 220 . https://doi.org/10.1016/j.it. 2016 . 01 . 004 PMID: 26858199
40. Narita Y , Wakita D , Ohkur T , Chamoto K , Nishimura T. Potential differentiation of tumor bearing mouse CD11b+Gr-1+ immature myeloid cells into both suppressor macrophages and immunostimulatory dendritic cells . Biomed Res . 2009 ; 30 ( 1 ):7± 15 . PMID: 19265258
41. Kusmartsev S , Gabrilovich DI . STAT1 signaling regulates tumor-associated macrophage-mediated T cell deletion . J Immunol . 2005 ; 174 ( 8 ): 4880 ± 91 . PMID: 15814715
42. Zhong H , Gutkin DW , Han B , Ma Y , Keskinov AA , Shurin MR , et al. Origin and pharmacological modulation of tumor-associated regulatory dendritic cells . Int J Cancer . 2014 ; 134 ( 11 ): 2633 ± 45 . https://doi.org/ 10.1002/ijc.28590 PMID: 24443321
43. Horan PK , Slezak SE . Stable cell membrane labelling . Nature . 1989 ; 340 ( 6229 ): 167 ±8. https://doi.org/ 10.1038/340167a0 PMID: 2662017
44. Lassailly F , Griessinger E , Bonnet D. "Microenvironmental contaminations" induced by fluorescent lipophilic dyes used for noninvasive in vitro and in vivo cell tracking . Blood . 2010 ; 115 ( 26 ): 5347 ± 54 . https:// doi.org/10.1182/blood-2009 -05-224030 PMID: 20215639
45. Griessinger CM , Maurer A , Kesenheimer C , Kehlbach R , Reischl G , Ehrlichmann W , et al. 64Cu antibody-targeting of the T-cell receptor and subsequent internalization enables in vivo tracking of lymphocytes by PET . Proc Natl Acad Sci U S A . 2015 ; 112 ( 4 ): 1161 ±6. https://doi.org/10.1073/pnas. 1418391112 PMID: 25587131
46. Griessinger CM , Kehlbach R , Bukala D , Wiehr S , Bantleon R , Cay F , et al. In vivo tracking of Th1 cells by PET reveals quantitative and temporal distribution and specific homing in lymphatic tissue . J Nucl Med . 2014 ; 55 ( 2 ): 301 ±7. https://doi.org/10.2967/jnumed.113.126318 PMID: 24434289
47. Ahrens ET , Bulte JW . Tracking immune cells in vivo using magnetic resonance imaging . Nat Rev Immunol . 2013 ; 13 ( 10 ): 755 ± 63 . https://doi.org/10.1038/nri3531 PMID: 24013185
48. Sceneay J , Smyth MJ , Moller A . The pre-metastatic niche: finding common ground . Cancer Metastasis Rev . 2013 ; 32 ( 3 ±4): 449 ± 64 . https://doi.org/10.1007/s10555-013 -9420-1 PMID: 23636348